Literature DB >> 25978968

Mineralocorticoid exposure and receptor activity modulate microvascular endothelial function in African Americans with and without hypertension.

Appesh Mohandas1, Tisha B Suboc2, Jingli Wang2, Rong Ying2, Sergey Tarima3, Kodlipet Dharmashankar2, Mobin Malik2, Michael E Widlansky4.   

Abstract

Prior work suggests blood pressure in African Americans is more sensitive to the effects of aldosterone than in Caucasians. This mechanism may relate to a negative response of the vascular endothelium to aldosterone, including reduced glucose-6-phosphate dehydrogenase (G6PD) activity. Thirty-three African Americans (11 hypertensives, 22 controls) without evidence of diabetes or metabolic syndrome completed the protocol. The protocol included measurement of in vivo microvascular endothelial function by digital pulse arterial tonometry and ex vivo measurement of endothelial function by videomicroscopy of arterioles obtained from these same subjects with and without exposure to aldosterone or spironolactone. Systemic and arteriolar G6PD activities were also measured. In vivo and ex vivo microvascular endothelial function were impaired in African Americans with hypertension. One-hour exposure with aldosterone impaired endothelium-dependent vasodilation in arterioles from normotensive subjects, while 1 hour of spironolactone exposure reversed endothelial dysfunction in arterioles from hypertensive subjects. G6PD activity was impaired in hypertensive arterioles. Aldosterone-related endothelial dysfunction may be responsible for at least a portion of the greater blood pressure sensitivity to aldosterone in African Americans. This may be in part related to vascular suppression of G6PD activity.
© The Author(s) 2015.

Entities:  

Keywords:  African American; aldosterone; endothelial function; hypertension; microvasculature

Mesh:

Substances:

Year:  2015        PMID: 25978968      PMCID: PMC5586595          DOI: 10.1177/1358863X15584753

Source DB:  PubMed          Journal:  Vasc Med        ISSN: 1358-863X            Impact factor:   3.239


  33 in total

1.  Racial differences in maximal vasodilatory capacity of forearm resistance vessels in normotensive young adults.

Authors:  D R Bassett; W J Duey; A J Walker; E T Howley; V Bond
Journal:  Am J Hypertens       Date:  1992-11       Impact factor: 2.689

2.  Impaired endothelial function in healthy African-American adolescents compared with Caucasians.

Authors:  Mary M Duck; Robert P Hoffman
Journal:  J Pediatr       Date:  2007-04       Impact factor: 4.406

3.  Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity.

Authors:  Jane A Leopold; Aamir Dam; Bradley A Maron; Anne W Scribner; Ronglih Liao; Diane E Handy; Robert C Stanton; Bertram Pitt; Joseph Loscalzo
Journal:  Nat Med       Date:  2007-02-04       Impact factor: 53.440

4.  Arterial pressure, left ventricular mass, and aldosterone in essential hypertension.

Authors:  A H El-Gharbawy; V S Nadig; J M Kotchen; C E Grim; K B Sagar; M Kaldunski; P Hamet; Z Pausova; D Gaudet; F Gossard; T A Kotchen
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

5.  Hyperaldosteronism and hypertension: ethnic differences.

Authors:  Clarence E Grim; Allen W Cowley; Pavel Hamet; Daniel Gaudet; Mary L Kaldunski; Jane Morley Kotchen; Shanthi Krishnaswami; Zdenka Pausova; Richard Roman; Johanne Tremblay; Theodore A Kotchen
Journal:  Hypertension       Date:  2005-02-07       Impact factor: 10.190

6.  Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991.

Authors:  V L Burt; P Whelton; E J Roccella; C Brown; J A Cutler; M Higgins; M J Horan; D Labarthe
Journal:  Hypertension       Date:  1995-03       Impact factor: 10.190

7.  Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy.

Authors:  Colin A J Farquharson; Allan D Struthers
Journal:  Clin Sci (Lond)       Date:  2002-10       Impact factor: 6.124

8.  A new sensitive chemiluminescence probe, L-012, for measuring the production of superoxide anion by cells.

Authors:  Y Nishinaka; Y Aramaki; H Yoshida; H Masuya; T Sugawara; Y Ichimori
Journal:  Biochem Biophys Res Commun       Date:  1993-06-15       Impact factor: 3.575

9.  Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors:  Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

Review 10.  Salt intake and hypertensive renal injury in African-Americans. A therapeutic perspective.

Authors:  M R Weir
Journal:  Am J Hypertens       Date:  1995-06       Impact factor: 2.689

View more
  5 in total

Review 1.  The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease.

Authors:  Ana P Davel; Imran J Anwar; Iris Z Jaffe
Journal:  Curr Opin Nephrol Hypertens       Date:  2017-03       Impact factor: 2.894

Review 2.  The endothelial mineralocorticoid receptor: Contributions to sex differences in cardiovascular disease.

Authors:  M Elizabeth Moss; Brigett Carvajal; Iris Z Jaffe
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

Review 3.  Drug Treatment of Hypertension: Focus on Vascular Health.

Authors:  Alan C Cameron; Ninian N Lang; Rhian M Touyz
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

4.  Modulation of transcriptional mineralocorticoid receptor activity by casein kinase 2.

Authors:  Stefanie Ruhs; Nicole Strätz; Katja Quarch; Antonia Masch; Mike Schutkowski; Michael Gekle; Claudia Grossmann
Journal:  Sci Rep       Date:  2017-11-10       Impact factor: 4.379

Review 5.  Mineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and Atherosclerosis.

Authors:  Mary E Moss; Iris Z Jaffe
Journal:  Front Endocrinol (Lausanne)       Date:  2015-09-28       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.